R . Prognostic significance of benign proliferative breast disease . Cancer 1993 ; 71 : 3896 – 3907 . 15. Fisher B Costantino JP Wickerham DL . Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast
Search Results
Evolving Concepts in the Management of Lobular Neoplasia
Benjamin O. Anderson, Kristine E. Calhoun, and Eric L. Rosen
NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry
D. Craig Allred, Robert W. Carlson, Donald A. Berry, Harold J. Burstein, Stephen B. Edge, Lori J. Goldstein, Allen Gown, M. Elizabeth Hammond, James Dirk Iglehart, Susan Moench, Lori J. Pierce, Peter Ravdin, Stuart J. Schnitt, and Antonio C. Wolff
comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98 . J Clin Oncol 2007 ; 25 : 3846 – 3852 . 12 Badve SS Baehner FL Gray RP . Estrogen- and progesterone-receptor status in ECOG 2197: comparison
NCCN Guidelines Insights: Breast Cancer, Version 1.2017
William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Janice Lyons, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena S. Moran, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dorothy A. Shead, and Rashmi Kumar
aged ≥70 years at diagnosis with clinical stage I, node-negative, ER-positive breast cancer with negative margins who were to receive adjuvant tamoxifen randomized patients to receive lumpectomy with WBRT or lumpectomy alone. With a median follow up of
Using Multigene Tests to Select Treatment for Early-Stage Breast Cancer
Rodrigo Goncalves and Ron Bose
that the Onco type DX score predicted the likelihood of distant recurrence or breast cancer death when treated with hormonal therapy alone. 8 , 9 Archival samples from the NSABP B-14 trial, which tested the use of tamoxifen in patients with estrogen
Adjuvant Chemotherapy Decisions in Clinical Practice for Early-Stage Node-Negative, Estrogen Receptor-Positive, HER2-Negative Breast Cancer: Challenges and Considerations
Gayathri Nagaraj and Cynthia X. Ma
literature. Although the proportional risk reduction from adjuvant polychemotherapy was found to be independent of ER status and tamoxifen use in the Oxford overview, 3 the relative chemoresistance of ER+ disease has been demonstrated in the neoadjuvant
Strategies for the Management of Early-Stage Breast Cancer in Older Women
Lee S. Schwartzberg and Sarah L. Blair
receiving breast-conserving surgery without RT versus mastectomy, and 6 times higher for those receiving tamoxifen for less than 1 year compared with 5 years or more. 8 However, based on a prospective randomized clinical trial, carefully selected patients
Evidence and Controversies in the Use of Post-Mastectomy Radiation
Shaneli A. Fernando and Stephen B. Edge
adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group . J Clin Oncol 1999 ; 17 : 1689 – 1700 . 3. Jagsi R Raad RA Goldberg S . Locoregional recurrence rates and prognostic
Diagnosis and Management of High-Risk Breast Lesions
Parijatham S. Thomas
(SERMs) and aromatase inhibitors (AIs) for the prevention of breast cancer. The Breast Cancer Prevention Trial (BCPT) evaluated 13,388 women aged ≥35 years with an elevated risk of breast cancer randomized to tamoxifen daily for 5 years or placebo
Impact of the Breast Cancer Index for Extended Endocrine Decision-Making: First Results of the Prospective BCI Registry Study
Tara B. Sanft, Jenna Wong, Brandon O’Neal, Natalia Siuliukina, Rachel C. Jankowitz, Mark D. Pegram, Jenny R. Fox, Yi Zhang, Kai Treuner, and Joyce A. O’Shaughnessy
, which has been shown to predict EET benefit across different adjuvant endocrine treatment regimens, including tamoxifen monotherapy, aromatase inhibitor (AI) monotherapy, and sequenced tamoxifen-AI. 19 – 24 The BCI Registry study is an ongoing
Bone Mineral Density Testing Disparities Among Patients With Breast Cancer Prescribed Aromatase Inhibitors
John Charlson, Elizabeth C. Smith, Alicia J. Smallwood, Purushottam W. Laud, and Joan M. Neuner
Background Aromatase inhibitors (AIs), tamoxifen, and the sequential use of these agents are all standard options for adjuvant hormonal therapy (HT) for postmenopausal women with early-stage, estrogen receptor (ER)–positive breast cancer. At
